Rajesh K. Malik
Technik-/Wissenschafts-/F&E-Leiter bei G1 THERAPEUTICS, INC.
Vermögen: 259 824 $ am 30.04.2024
Profil
Rajesh K.
Malik's current job(s) include being the Director at Meryx, Inc. since 2018 and the Chief Medical Officer at G1 Therapeutics, Inc. since 2014.
Dr. Malik's former job(s) include being an Associate Director at Bristol Myers Squibb Co. from 2000 to 2002, an Executive Director at EMD Pharmaceuticals, Inc. from 2002 to 2004, a Director & Chief Medical Officer at Agennix AG from 2007 to 2013, an Independent Director at POINT Biopharma Global, Inc. from 2021 to 2023, and the Chief Medical Officer at Fennec Pharmaceuticals, Inc. from 2004 to 2007.
Dr. Malik also held the position of Assistant Professor at the University of Virginia and Chief Medical Officer at Agennix, Inc.Dr. Malik obtained a doctorate degree from the University of Sheffield Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
G1 THERAPEUTICS, INC.
0,13% | 13.05.2024 | 67 312 ( 0,13% ) | 259 824 $ | 30.04.2024 |
Aktive Positionen von Rajesh K. Malik
| Unternehmen | Position | Beginn |
|---|---|---|
| G1 THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2014 |
Meryx, Inc.
 Meryx, Inc. Pharmaceuticals: MajorHealth Technology Meryx, Inc. operates as an immune-oncology company. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancer, such as leukemia, lung cancer, and melanoma. The company was founded by Doug Graham, Shelley Earp, and Stephen Frye in 2007 and is headquartered in Chapel Hill, NC. | Direktor/Vorstandsmitglied | 01.05.2018 |
Ehemalige bekannte Positionen von Rajesh K. Malik
| Unternehmen | Position | Ende |
|---|---|---|
| POIT BIOP | Direktor/Vorstandsmitglied | 27.12.2023 |
| AGENNIX AG | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 |
| FENNEC PHARMACEUTICALS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2007 |
EMD Pharmaceuticals, Inc.
 EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | Direktor/Vorstandsmitglied | 01.01.2004 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von Rajesh K. Malik
| University of Sheffield Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| POIT BIOP | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Agennix, Inc.
 Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Health Technology |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | Health Technology |
Agennix AG
 Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
Meryx, Inc.
Meryx, Inc. Pharmaceuticals: MajorHealth Technology Meryx, Inc. operates as an immune-oncology company. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancer, such as leukemia, lung cancer, and melanoma. The company was founded by Doug Graham, Shelley Earp, and Stephen Frye in 2007 and is headquartered in Chapel Hill, NC. | Health Technology |